Effects of Nectin-4 targeted Bicycle Toxin Conjugate, zelenectide pevedotin (BT8009), and enfortumab vedotin on a human corneal tissue model

被引：0
|
作者：
Kristensson, J. [1 ]
Campbell, C. [2 ]
Ludbrook, S. [1 ]
Hirschberg, S. [3 ]
Rigby, M. [1 ]
机构：
[1] BicycleTx, Biol, Cambridge, England
[2] BicycleTx, Translat, Boston, MA USA
[3] BicycleTx, Clin, Cambridge, England
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114817
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB292
引用
收藏
页码：S115 / S115
页数：1
相关论文
共 10 条
  • [1] BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
    Rigby, Michael
    Bennett, Gavin
    Chen, Liuhong
    Mudd, Gemma E.
    Harrison, Helen
    Beswick, Paul J.
    Van Rietschoten, Katerine
    Watcham, Sophie M.
    Scott, Heather S.
    Brown, Amy N.
    Park, Peter U.
    Campbell, Carly
    Haines, Eric
    Lahdenranta, Johanna
    Skynner, Michael J.
    Jeffrey, Phil
    Keen, Nicholas
    Lee, Kevin
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) : 1747 - 1756
  • [2] Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
    Mudd, Gemma E.
    Scott, Heather
    Chen, Liuhong
    van Rietschoten, Katerine
    Ivanova-Berndt, Gabriela
    Dzionek, Katarzyna
    Brown, Amy
    Watcham, Sophie
    White, Lewi
    Park, Peter U.
    Jeffrey, Phil
    Rigby, Mike
    Beswick, Paul
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (21) : 14337 - 14347
  • [3] A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).
    Loriot, Yohann
    Siefker-Radtke, Arlene O.
    Friedlander, Terence W.
    Necchi, Andrea
    Wei, Alexander Z.
    Sridhar, Srikala S.
    Garmezy, Benjamin
    Arroyo, Santiago
    Gartside, Emma
    Liu, Jie
    Campbell, Carly
    Bader, Justin
    Petrylak, Daniel P.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : TPS898 - TPS898
  • [4] Molecular-based enrichment strategy for Nectin-4 targeted Bicycle toxin conjugate BT8009.
    Gelb, Tara
    Santos, Sean
    Dickson, Amy
    Campbell, Carly
    Rigby, Mike
    Mckenzie, Andrew J.
    Rozelle, Dan
    Blakemore, Stephen J.
    CANCER RESEARCH, 2021, 81 (13)
  • [5] BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
    Rigby, Michael
    Bennett, Gavin
    Chen, Liuhong
    Mudd, Gemma
    Beswick, Paul
    Harrison, Helen
    Watcham, Sophie
    Allen, Heather
    Brown, Amy
    Van Rietschoten, Katerine
    Jeffrey, Philip
    Park, Peter U.
    Haines, Eric
    Keen, Nicholas
    Lahdenranta, Johanna
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [6] BT8009: A bicyclic peptide toxin conjugate targeting Nectin-4 (PVRL4) displays efficacy in preclinical tumor models
    Rigby, Mike
    Beswick, Paul
    Mudd, Gemma
    Van Rietschoten, Katerine
    Chen, Liuhong
    Watcham, Sophie M.
    Allen, Heather
    Brown, Amy
    Harrison, Helen
    Bennett, Gavin
    Jeffrey, Phil
    Park, Peter U.
    Koehler, Maria
    Keen, Nicholas
    CANCER RESEARCH, 2019, 79 (13)
  • [7] A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2
    Loriot, Yohann
    Siefker-Radtke, Arlene O.
    Friedlander, Terence W.
    Necchi, Andrea
    Wei, Alexander Z.
    Sridhar, Srikala S.
    Garmezy, Benjamin
    Arroyo, Santiago
    Gartside, Emma
    Liu, Jie
    Campbell, Carly
    Bader, Justin
    Petrylak, Daniel P.
    Roussy, Gustave
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression
    McKean, Meredith
    Baldini, Capucine
    Verlingue, Loic
    Doger, Bernard
    Falchook, Gerald
    Italiano, Antoine
    Lostes, Julia
    Reig, Oscar
    Watson, Roshawn
    Hazard, Sebastien
    Smethurst, Dominic
    Fulci, Giulia
    Xu, Hongmei
    Jeffery, Phil
    Lee, Kevin
    Brana, Irene
    Cousin, Sophie
    Fontana, Elisa
    Arkenau, Hendrik-Tobias
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.
    McKean, Meredith
    Falchook, Gerald Steven
    Bendell, Johanna C.
    Bashir, Babar
    Palmisiano, Neil
    Watson, Roshawn
    McKenna, Mary-Anne
    Campbell, Carly
    Smethurst, Dominic Paul
    Jeffrey, Phil
    Kirui, Julius
    Arkenau, Hendrik-Tobias
    Fontana, Elisa
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
    Baldini, Capucine
    Goldschmidt, Vincent
    Brana, Irene
    Doger, Bernard
    Italiano, Antoine
    Cousin, Sophie
    Falchook, Gerald Steven
    Necchi, Andrea
    Reig, Oscar
    Carter, Louise
    Fontana, Elisa
    Verlingue, Loic
    Hazard, Sebastien
    Dickson, Amy
    Xu, Cong
    Xu, Hongmei
    Sharma, Rajiv
    Smethurst, Dominic
    McKean, Meredith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
1